Companies will collaborate on antibody discovery against multiple targets. Vaccines company Sanofi Pasteur is paying Vivalis €3 million up front for exclusive access to the latter’s Humalex® platform ...

LONDON (Reuters) - France's Vivalis is set to buy Intercell in a deal valuing the Austrian vaccine maker at around 133 million euros ($174 million), and creating an enlarged player in the European ...

Companies will work together to fine-tune the platform for production of the MVA component. GeoVax Labs plans to use Vivalis’ EBx® technology to manufacture the MVA component of the its HIV-1 vaccine.

Six months after acquiring the Humalex antibody platform from Humalys, Vivalis SA secured its first license agreement for the technology, a wide-ranging alliance in infectious disease with Paris-based ...